Hormonal in Medical Technology

Methadone Frequently Causes Menopausal Symptoms in Young Women

... even in women less than thirty years old. hormonal suppression, caused by methadone, can cause ... University of Pennsylvania study revealed severe hormonal suppression caused by narcotic pain medications. ... prescribing methadone failed to inform them of hormonal suppression risks caused by methadone. ...

New Mammography Technology Effective in Detecting Breast Cancer

... affected by either breast density or a woman's hormonal status, two factors that limit the effectiveness ... believe these false positives are due in part to hormonal changes that occur during a woman's menstrual ... whose MRI is difficult to interpret due to hormonal influences, women with implants, patients with ...

Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being

... study showing that non-compliance with combined hormonal contraceptives has noticeable effects on women's ... current users, aged 18 to 49, of three combined hormonal contraceptive methods, the combined pill, the ... in women over 35; women who use combination hormonal contraceptives are strongly advised not to ...

ORTHO EVRA(R) Prescribing Information Updated

... USING ORTHO EVRA section. ORTHO EVRA is a hormonal birth control option and is safe and ... on this label change. ORTHO EVRA, like all hormonal birth control, has risks and benefits. It is ... side effects have been reported with the use of hormonal contraceptives. Serious risks include blood ...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

... "the change of life": MacaLife(R) for peri-menopausal women experiencing hormonal fluctuations, and MacaPause(R) for post-menopausal women experiencing ... after menopause, such as heart health, bone health, mental health and hormonal balance. About Natural Health International Natural Health ...

Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

... by ovulation suppression), cycle control and tolerability at the lowest hormonal dose. Top-line results from the trial showed there was a clear ... to fill a sizeable need in the $6 billion global ($2.5 billion U.S.) hormonal contraceptive market. About Estrogen Estrogen is associated with ...

New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF

... for clear information on the cost-effectiveness, as well as the efficacy of individual treatments.[2] HP-hMG and rFSH are two commonly used hormonal therapies belonging to the class of drugs known as gonadotropins that enhance egg production in IVF treatment. HP-hMG, contains both FSH and ...

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women

... also some differences. For example, male breast cancer patients had higher mean expression of the hormone receptor genes, likely due to the different hormonal context of men and women. In addition, male breast cancer patients were older, on average, and were less likely than women to have the lobular form ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... in development by Novartis. Femara BIG 1-98 data on cognitive function Impaired cognition is a concern among breast cancer patients taking hormonal therapies. Estrogen is believed to have a direct influence on cognitive function. Aromatase inhibitors reduce the level of circulating estrogen in ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... deaths (American Cancer Society, Cancer Facts and Figures 2009). CRPC is prostate cancer that continues to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with ...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

... deaths (American Cancer Society, Cancer Facts and Figures 2009). CRPC is prostate cancer that continues to grow despite current standard of care hormonal (anti-androgen) therapies. CRPC is more invasive and more likely to spread to other organs than androgen dependent prostate cancers. Patients with ...

Study Confirms: Your Hidden Food Allergies Are Making You Fat

... an average decrease of 30% of body fat. Dr. Fred Pescatore, former Medical Director of the famed Atkins Center and a pioneer in the study of the hormonal and immune system effects of foods, reviewed the findings and said, "I'm not surprised by these results, dramatic as they may appear. I've used the ...

Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th

... and physical therapists. Throughout the day, these experts will be available for one-on-one questions. Topics at the event include Managing hormonal Imbalances through Bio-Identical Hormone Replacement Therapy; The 3 Fundamental Keys to Wellness; A Decision Tree for Vibrant Living; Depression Free ...

Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production

... in the treatment of acne, which until recently has been treated almost exclusively - and with varying degrees of success - with topical, systemic and hormonal medications," said Dr. Alexiades-Armenakas. "Now, we have solid evidence-based medicine supporting the effectiveness of certain laser therapies as a ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... from solid tumors in conjunction with standard antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy. Important safety information Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other ...

Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

... to Phase 3 clinical trials next year. The open-label, U.S. Phase 1-2 study evaluated prostate cancer patients who had failed standard hormonal therapies, including men who had also failed standard chemotherapy regimens. A total of 140 men were enrolled in the trial, which evaluated doses ...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

... another inflammatory disease affecting the joints. While the exact cause of the disease is unknown, it is believed that both genetic and hormonal factors play a role. It is also known that the TNF-alpha pathway plays a role in the progression of the disease. Other companies have successfully ...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... Cancer Index will identify, among patients with early stage breast cancer, those with a higher risk of treatment failure when treated only with hormonal therapy. They concluded that the Theros Breast Cancer Index identified approximately 25 percent of grade 1 and grade 2 breast cancers that had a ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... from solid tumors in conjunction with standard antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy. Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients ...

New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes

... markets. The core therapeutic areas in Orion's product and research strategy are central nervous system disorders, cardiology, critical care and hormonal and urological therapies. Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both ...

Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness

... and explain the safety advantages of this more highly selective estrogen receptor modulator, VG101, when compared to the currently available hormonal therapies for this indication. The presentation will detail the complete analysis of VG101 in both in vivo and in vitro models as well as present the ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... is unblinded at an individual patient level. At that time we will be able to make correlations between pain scores, BMD, pharmacokinetic values, and hormonal levels on an individual patient basis, and we look forward to also sharing those results, as soon as they are available." Treatment with elagolix ...

Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation

... each associated with an overactive adrenergic system, a group of hormones produced by the adrenal glands that regulate the body's reaction to stress, hormonal fluctuations and myriad environmental factors. To identify new drug candidates, Addrenex will delve into its vast library of 400 adrenergic ...

Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting

... (80 percent) had stabilization of disease. Prior to enrollment in this study, all these patients had progressive disease despite standard-of-care hormonal therapies, and in roughly half the patients, also chemotherapy. As opposed to most previous studies in CRPC that have used the RECIST criteria to ...

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO

... the high frequency of responses and how rapidly they occur," said Steven I. Sherman, MD, Chair and Professor, Department of Endocrine Neoplasia and hormonal Disorders, University of Texas M.D. Anderson Cancer Center, Houston, Texas. "I am looking forward to the phase 3 trial of XL184 in this indication ...

Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women

... and targeted interventions to increase earlier detection of breast cancer in African-Americans, increase the percentage of patients that receive hormonal therapy when it is indicated, and include management of co-morbid conditions. "BCBSGA and other WellPoint companies are developing approaches ...

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

... from solid tumors in conjunction with standard antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy. Important Safety Information Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or ...

Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting

... Medivation's ongoing Phase 1-2 trial of MDV3100 is an open-label dose-escalation study enrolling prostate cancer patients who have failed standard hormonal therapies. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression. Medivation ...

Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause

... markets. The core therapeutic areas in Orion's product and research strategy are central nervous system disorders, cardiology, critical care and hormonal and urological therapies. Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both ...

Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer

... Avastin in combination with standard chemotherapies compared to chemotherapies alone in 2,530 planned patients who are not candidates for hormonal therapy. In addition, Avastin is being investigated in HER-2 positive breast cancer patients post surgery via the BETH trial. This study ...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

... or breast-feed while taking ATRIPLA. Barrier contraception must always be used in combination with other methods of contraception (eg, oral or other hormonal contraceptives). If the patient becomes pregnant while taking ATRIPLA, she should be apprised of the potential harm to the fetus. Mild-to-moderate ...

Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders

... biologic mechanisms of fever-specific effects in autism by conducting blood tests during and after fever and analyzing immune measurements and hormonal changes in the blood. This research study was the work of senior author Dr. Andrew Zimmerman of the Kennedy Krieger Institute and the doctoral thesis ...

Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

... utilized in the Company's currently approved and marketed products SUPPRELIN(R) LA and VANTAS(R). About Acromegaly Acromegaly is a chronic hormonal disorder that occurs when a pituitary tumor produces excess growth hormone, or GH. It most commonly affect middle- aged adults, and if untreated, ...

Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial

... to date in both dose groups. The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is enrolling patients in up to seven dose groups of three patients each at escalating doses, with each group continuing ...

Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease

... studies being conducted may soon yield an effective nonhormonal treatment. While there are several breast cancer drugs on the market, all available hormonal therapies have significant adverse events. In contrast, IoGen is a nonhormonal treatment that allows for safe long-term use with little or no side ...

Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD

... acids in the treatment of chronic disease conditions. He is the author of the New York Times #1 bestseller The Zone as well as 11 other books on his hormonal control technology, including The OmegaRx Zone and The Anti-Inflammation Zone. His books have sold more than 5 million copies in the United States ...

One-Third of Patients Discontinue Common Breast Cancer Therapy

... taking the standard five-year regimen of the hormonal breast cancer treatment tamoxifen citrate, ... and to raise awareness importance of hormonal therapy in breast cancer. WHAT: Dr. Vahdat is ... SOLTAMOX is the only liquid form of the hormonal breast cancer therapy, tamoxifen, approved by the ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... other vaccines has not been studied. Use with hormonal Contraceptives In clinical studies, 13,293 ... = 6649) who had post-Month 7 follow-up used hormonal contraceptives for a total of 17,597 ... the total follow-up time in the studies). Use of hormonal contraceptives or lack of use of hormonal ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... other vaccines has not been studied. Use with hormonal Contraceptives In clinical studies, 13,293 ... = 6649) who had post-Month 7 follow-up used hormonal contraceptives for a total of 17,597 ... the total follow-up time in the studies). Use of hormonal contraceptives or lack of use of hormonal ...